Posted by Michael Wonder on 25 May 2020
CADTH sees green for Beovu
25 May 2020 - CADTH has published its final recommendation for Novartis' Beovu.
CADTH's Canadian Drug Expert Committee has recommended that brolucizumab should be reimbursed for the treatment of nAMD only if certain conditions are met.
One condition is that the drug plan cost of treatment with brolucizumab should not exceed the drug plan cost of the least costly treatment reimbursed for neovascular (wet) age-related macular degeneration.
